35 reports

  • Epistem Holdings Plc Pipeline Products by Indication
  • Epistem Holdings Plc Pipeline Products Summary by Development Stage

It identifies the key regulators of cells in the disease areas such as cancer, gastrointestinal disease and wound healing.

  • Tuberculosis
  • India
  • World
  • Epistem Holdings Plc
  • GlobalData's company
  • Profiles of Tuberculosis Drugs Producers

APIs such as alleviate fever & analgesia, semi-synthetic antibiotics, cardiograph, anti-tuberculosis and gastrointestinal spasms are mainly produced in SIPC.

  • Tuberculosis
  • China
  • Demand
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd

The magnitude of the impact has been categorized as: ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Low High High Low High Low ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## High Prevalence of TB Initiatives and Funding ## ## ## ## ## ## ## ## ## ## Impact on Geography EM

  • Tuberculosis
  • World
  • Market Size
  • Alere Inc.
  • Roche Group
  • Ethambutol Producer
  • Profiles of Tuberculosis Drugs Producers

APIs such as alleviate fever & analgesia, semi-synthetic antibiotics, cardiograph, anti-tuberculosis and gastrointestinal spasms are mainly produced in SIPC.

  • Tuberculosis
  • China
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd
  • Shenyang Shuangding Pharmaceutical Co., Ltd.
  • DESCRIPTION OF INFECTIONS

Other viruses that cause gastrointestinal symptoms include adenoviruses, parvoviruses and astroviruses.

  • Tuberculosis
  • Cepheid
  • Getinge Group
  • Roche Group
  • STERIS Corporation

The several types of TB based on the site of infection are pulmonary TB (lungs), skeletal TB (bone and joints), pleural TB, lymph node TB, gastrointestinal TB, and TB meningitis.

  • Pathology
  • Tuberculosis
  • World
  • Company Financials
  • Market Size

The molecules developed by companies in Phase I, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC

Selling and marketing expenses decreased $ ##, ##, or ##. ## %, for the year ended December ## ##, 2014 as compared to the year ended December ## ##, 2013 as we decreased our selling efforts in the first nine months of the year due to our lack of capital.

  • Infectious Disease
  • Tuberculosis
  • Japan
  • United States
  • GlobalData's company

Resolor is part of Shire' s gastrointestinal (GI) portfolio in Europe and is approved for use in ## countries.

  • Tuberculosis
  • Belgium
  • United States
  • Company
  • Janssen Biotech, Inc.
  • TNP-2092 - DRUG PROFILE
  • TNP-2092 - DRUG PROFILE

Although they were found not to be suitable in treating TB, they may hold value in treating infectious diseases of the gastrointestinal (GI) tract.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • AmpliPhi Biosciences Corporation
  • Global Markets Direct Report Coverage

The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are ##, ## and ## respectively.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.
  • Global Markets Direct Report Coverage

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.

The data were presented at the 2016 Gastrointestinal Cancers Symposium (ASCO GI).

  • Breast Cancer
  • Monoclonal Antibody
  • Therapy
  • Tuberculosis
  • Daiichi Sankyo Company
  • 5.3.1 Antibacterial Disease Overall

However, marketed anthrax vaccines are not effective against gastrointestinal anthrax, which even when treated with proper antibiotics is fatal in ##% of patients.

  • Anti-Infective
  • Therapy
  • Tuberculosis
  • World
  • Deals & Alliance

Selling and marketing expenses decreased $ ##, ##, or ##. ## %, for the year ended December ## ##, 2014 as compared to the year ended December ## ##, 2013 as we decreased our selling efforts in the first nine months of the year due to our lack of capital.

  • Infectious Disease
  • Tuberculosis
  • Japan
  • United States
  • GlobalData's company
  • MAY 02, 2018: QIAGEN ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

QIAGEN ANNOUNCES NEW $## MILLION SHARE REPURCHASE COMMITMENT QIAGEN HAS ENTERED INTO A PURCHASE AGREEMENT TO ACQUIRE STAT-DX, A PRE-COMMERCIAL COMPANY DEVELOPING ADVANCED MULTIPLEX DIAGNOSTICS FOR ONE-STEP, FULLY INTEGRATED MOLECULAR ANALYSIS OF COMMON SYNDROMES SUCH AS SERIOUS RESPIRATORY

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • Company Financials
  • QIAGEN N.V.
  • TENNOR ACQUIRES PATENTS FROM TB ALLIANCE

Although they were found not to be suitable in treating TB, they may hold value in treating infectious diseases of the gastrointestinal (GI) tract.

  • Pathology
  • Tuberculosis
  • World
  • Company
  • TB Drug Development, Inc.

GlobalData Cepheid' s, deal volume decreased from two medical equipment deals in 2016 to one medical equipment deal in 2017.

  • Medical Supply
  • Tuberculosis
  • United States
  • M&A
  • Cepheid
  • Recent Developments

THE INITIAL LAUNCH IN EUROPE, WITH PANELS FOR EVALUATION OF RESPIRATORY AND GASTROINTESTINAL INFECTIONS, WILL BE FOLLOWED BY A DEEP PIPELINE OF OTHER ASSAYS.

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • World
  • QIAGEN N.V.

Q. ##.

  • Tuberculosis
  • North America
  • United States
  • Market Size
  • Alere Inc.
  • Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases

One study recruits children as young as one year old with a particularly aggressive form of neuroblastoma.

  • Cancer
  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States

GlobalData Region North America Asia-Pacific Europe Middle East and Africa South and Central America No. of Deals ## ## ## ## ## Deal Value (US$ million) ##. ## NA NA NA NA Sequella Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 Sequella I

  • Healthcare
  • Pharmaceutical
  • Tuberculosis
  • United States
  • Deals & Alliance
  • TUBERCULOSIS - PIPELINE BY AKTHELIA PHARMACEUTICALS LIMITED,
  • TUBERCULOSIS - PIPELINE BY GANGAGEN INC.,

The company' s products are used in ophthalmological, gastrointestinal, laxative, and contrast media applications.

  • Biotech
  • Tuberculosis
  • United States
  • Company
  • Product Initiative
  • TUBERCULOSIS - PIPELINE BY PFIZER INC, H2 2017
  • DELAMANID

Tuberculosis - Overview Tuberculosis - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR TUBERCULOSIS, H## 2017 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR TUBERCULOSIS, H## 2017 Pre-Registration ## ## Phase III ## ## Phase II ## ## Phase I ## ## IND/ CTA Filed

  • Pathology
  • Tuberculosis
  • Vaccine
  • World
  • TB Drug Development, Inc.

One: Executive Summary ## TABLE ##-## APPLICATIONS COMMONLY RUN ON READER SYSTEMS Gene expr.

  • Bioinformatic
  • In Vitro Diagnostics
  • Molecular Diagnostic
  • Tuberculosis
  • Illumina, Inc.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Tuberculosis
  • World
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

The prominent features of this report are - ##.

  • Anti-Infective
  • Clinical Trial
  • Infectious Disease
  • Tuberculosis
  • World
  • Clinical Trial profile. 109 Trial Title
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Anti-Infective
  • Therapy
  • Tuberculosis
  • World
  • Product Initiative
  • TUBERCULOSIS - PIPELINE BY NOVOBIOTIC PHARMACEUTICALS LLC, H1 2018
  • TUBERCULOSIS - PIPELINE BY NOVARTIS AG, H1 2018

Tuberculosis - Overview Tuberculosis - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR TUBERCULOSIS, H## 2018 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR TUBERCULOSIS, H## 2018 Pre-Registration ## ## Phase III ## ## Phase II ## ## Phase I ## ## IND/ CTA Filed ##

  • Pathology
  • Tuberculosis
  • Vaccine
  • United States
  • TB Drug Development, Inc.

DEAL IN BRIEF PARTNER ##: MERCK & CO., INC.

  • Tuberculosis
  • United States
  • Company
  • Corporate Finance
  • Anacor Pharmaceuticals, Inc.